FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Oncologist - United States
doi 10.1634/theoncologist.2019-0098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
2019English

Redefining the Role of Etoposide in First-Line Treatment of Peripheral T-Cell Lymphoma

Blood advances
Hematology
2017English

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Effects of First-Line Chemotherapy on Natural Killer Cells in Adult T-Cell Leukemia–lymphoma and Peripheral T-Cell Lymphoma

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Brentuximab-Vedotin and Bendamustine Is a Feasible and Effective Drug Combination as First-Line Treatment of Hodgkin Lymphoma in the Elderly (Halo Trial)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Polatuzumab Vedotin: First Global Approval

Drugs
Pharmacology
2019English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy